Pharsight

Alphagan P patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5424078

(Pediatric)

ABBVIE Aqueous ophthalmic formulations and methods for preserving same
Dec, 2012

(11 years ago)

US9295641 ABBVIE Compositions containing alpha-2-adrenergic agonist components
Jul, 2021

(2 years ago)

US9687443 ABBVIE Compositions containing alpha-2-adrenergic agonist components
Jul, 2021

(2 years ago)

US10307368 ABBVIE Compositions containing alpha-2-adrenergic agonist components
Jul, 2021

(2 years ago)

US6562873 ABBVIE Compositions containing therapeutically active components having enhanced solubility
Jul, 2021

(2 years ago)

US6627210 ABBVIE Compositions containing α-2-adrenergic agonist components
Jul, 2021

(2 years ago)

US6673337 ABBVIE Compositions containing alpha-2-adrenergic agonist components
Jul, 2021

(2 years ago)

US6641834 ABBVIE Compositions containing alpha-2-adrenergic agonist components
Jul, 2021

(2 years ago)

US9687443

(Pediatric)

ABBVIE Compositions containing alpha-2-adrenergic agonist components
Jan, 2022

(2 years ago)

US6562873

(Pediatric)

ABBVIE Compositions containing therapeutically active components having enhanced solubility
Jan, 2022

(2 years ago)

US9295641

(Pediatric)

ABBVIE Compositions containing alpha-2-adrenergic agonist components
Jan, 2022

(2 years ago)

US6627210

(Pediatric)

ABBVIE Compositions containing α-2-adrenergic agonist components
Jan, 2022

(2 years ago)

US6673337

(Pediatric)

ABBVIE Compositions containing alpha-2-adrenergic agonist components
Jan, 2022

(2 years ago)

US6641834

(Pediatric)

ABBVIE Compositions containing alpha-2-adrenergic agonist components
Jan, 2022

(2 years ago)

US8858961 ABBVIE Compositions containing alpha-2-adrenergic agonist components
Sep, 2023

(9 months ago)

US8858961

(Pediatric)

ABBVIE Compositions containing alpha-2-adrenergic agonist components
Mar, 2024

(3 months ago)

Alphagan P is owned by Abbvie.

Alphagan P contains Brimonidine Tartrate.

Alphagan P has a total of 16 drug patents out of which 16 drug patents have expired.

Expired drug patents of Alphagan P are:

  • US5424078*PED
  • US9295641
  • US9687443
  • US10307368
  • US6562873
  • US6627210
  • US6673337
  • US6641834
  • US9687443*PED
  • US6562873*PED
  • US9295641*PED
  • US6627210*PED
  • US6673337*PED
  • US6641834*PED
  • US8858961
  • US8858961*PED

Alphagan P was authorised for market use on 16 March, 2001.

Alphagan P is available in solution/drops;ophthalmic dosage forms.

Alphagan P can be used as reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.

The generics of Alphagan P are possible to be released after 02 March, 2024.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using BRIMONIDINE TARTRATE ingredient

Market Authorisation Date: 16 March, 2001

Treatment: Reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of ALPHAGAN P before it's drug patent expiration?
More Information on Dosage

ALPHAGAN P family patents

Family Patents